Systematic Characterization of the Computed Tomography Angiography Spot Sign in Primary Intracerebral Hemorrhage Identifies Patients at Highest Risk for Hematoma Expansion: The Spot Sign Score
Stroke 40:2994-3000, Delgado,J.,et al, 2009
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage
JAMA Neurol 8:363-372, Sheth,K.M.,et al, 2024
Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019
Management of Bleeding in Patients Taking Oral Anticoagulants
JAMA 319:2032-2033, Anderson, I.,et al, 2018
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Intracerebral Haemorrhage: Current Approaches to Acute Management
Lancet 392:1257-1268, Cordonnier, C.,et al, 2018
Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke
Stroke 48:e343-e361, Yaghi, S.,et al, 2017
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
Hemostatic Therapy Should be Used for Acute Treatment of Anticoagulation-Related Intracerebral Hemorrhage
Stroke 43:2535-2536,2539, Diringer, M. & Zazulia, A.R., 2012
Hemostatic Therapy Should not be Used for Acute Treatment of Anticoagulation-Related Intracerebral Hemorrhage
Stroke 43:2537-2538,2539, Stapf, C., 2012
Can a Subset of Intracerebral Hemorrhage Patients Benefit from Hemostatic Therapy with Recombinant Activated Factor VII?
Stroke 40:833-840, Mayer,S.A.,et al, 2009
Hemostatic Drug Therapies for Acute, Nontraumatic Intracerebral Hemorrhage
Stroke 38:204-205, Al-Shahi,R. &You,H., 2007